期刊
PSYCHOPHARMACOLOGY
卷 212, 期 2, 页码 181-191出版社
SPRINGER
DOI: 10.1007/s00213-010-1943-3
关键词
Phosphodiesterase-4 (PDE4); Rolipram; beta-Amyloid peptide (A beta); Alzheimer's disease; Memory; CREB
资金
- National Institute of Aging [AG031687]
- NARSAD Young Investigator Awards
- National Natural Science Foundation of China [30672453, 30973518]
- Guangdong Natural Science Foundation, China [7117782]
Cyclic AMP signaling plays an important role in memory loss associated with Alzheimer's disease (AD). However, little is known about whether inhibition of phosphodiesterase-4 (PDE4), which increases intracellular cAMP, reverses beta-amyloid peptide (A beta)-induced memory deficits. Experiments were performed to demonstrate the effect of the PDE4 inhibitor rolipram on memory impairment produced by A beta 1-40 (A beta 40) or its core fragment A beta 25-35. We tested memory using Morris water-maze and passive avoidance tasks and examined expression of phosphorylated cAMP response-element binding protein (pCREB) in the hippocampus in rats treated with A beta 25-35 or A beta 40 into bilateral CA1 subregions, with or without rolipram administration. A beta 25-35 (10 mu g/side) increased escape latency during acquisition training and decreased swimming time and distance in the target quadrant in the water-maze probe trial; it also decreased 24-h retention in the passive avoidance paradigm. All these were reversed by chronic administration of rolipram (0.5 mg/kg). Similarly, A beta 40 (4 mu g/side) produced memory impairment, as demonstrated by decreased retention in passive avoidance; this was also reversed by repeated treatment with rolipram. In addition, rolipram blocked extinction of memory during the 32-day testing period in the passive avoidance test. Further, A beta 40 decreased pCREB expression in the hippocampus, which was also reversed by rolipram; the changes in pCREB were highly correlated with those in memory. These results suggest that the PDE4 inhibitor rolipram reverses cognitive deficits associated with AD most likely via increased cAMP/CREB signaling in the hippocampus; PDE4 could be a target for drugs that improve cognition in AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据